ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida. Details and highlights may be found below. Addition of Two New Directors Allesandro PudduAlessandro Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory and financial reporting for ...

Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreem ...

The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum TechnologyORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta LLC and its subsidiaries, Qvanta Foundry LLC and ...

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. Illicit fentanyl and its core precursor chemicals have been designated as weapons of mass destruction to enable the US government to combat the manufacture and distribution by cartels and foreign networks that have flooded the US with illegal fentanyl. Nut ...

Revenue Performance - Revenue for the three months ended October 31, 2025, was $346,058, a decrease from $645,796 in the same period of 2024, representing a decline of approximately 46.4%[11] - For the nine months ended October 31, 2025, revenue increased to $1,635,942, compared to $1,497,158 for the same period in 2024, reflecting a growth of about 9.3%[11] - Total revenue for the nine months ended October 31, 2025, was $1,635,942, an increase from $1,497,158 for the same period in 2024, representing an 9.3% growth[40] - Revenue from the sale of goods in the three months ended October 31, 2025, was $346,058, compared to $645,796 in the same period of 2024, indicating a decline of 46.4%[40] Net Loss and Expenses - The net loss for the three months ended October 31, 2025, was $3,872,367, compared to a net loss of $1,362,637 for the same period in 2024, representing an increase in loss of about 184.5%[11] - The company reported a net loss available to common stockholders of $29,075,739 for the nine months ended October 31, 2025, compared to $4,966,179 for the same period in 2024, indicating a significant increase in loss[11] - For the nine months ended October 31, 2025, the company reported a net loss of $7,261,573, compared to a net loss of $4,966,179 for the same period in 2024[18] - Selling, general and administrative expenses for the three months ended October 31, 2025, were $3,491,728, significantly higher than $737,102 in the same period of 2024, an increase of about 373.5%[11] - Selling, general and administrative expenses for the nine months ending October 31, 2025, were $6,071,320, a significant increase from $2,554,155 in the same period of 2024, primarily due to higher equity-based expenses[126] Research and Development - Research and development expenses for the nine months ended October 31, 2025, were $1,703,093, down from $2,629,278 in the same period of 2024, a decrease of approximately 35.2%[11] - Research and development expenses for the Aversa Fentanyl product were $457,113 for the three months ending October 31, 2025, down from $880,768 in 2024, mainly due to reduced labor costs[122] - Research and development expenses for the Aversa Fentanyl product amounted to $1,703,093 for the nine months ending October 31, 2025, down from $2,629,278 in the same period of 2024, mainly due to reduced labor costs[127] Assets and Liabilities - Total current assets as of October 31, 2025, were $5,815,064, up from $4,794,265 as of January 31, 2025, indicating an increase of approximately 21.3%[9] - Total liabilities as of October 31, 2025, were $870,208, a decrease from $1,041,050 as of January 31, 2025, reflecting a reduction of approximately 16.4%[9] - Cash and cash equivalents increased to $5,312,177 as of October 31, 2025, from $4,311,719 as of January 31, 2025, representing a growth of approximately 23.2%[9] - As of October 31, 2025, the company had cash and cash equivalents of $5,312,177 and working capital of $5,042,529[29] Financing and Capital Structure - The company received proceeds of $5,305,503 from the exercise of warrants during the nine months ended October 31, 2025[29] - The company entered into a three-year $5,000,000 Credit Line Note facility with a related party to fund research and development of its Aversa product[29] - The Company entered an amended Credit Line Note agreement for an increased $5,000,000 credit line facility, with outstanding advances bearing interest at 7% per annum[65] - The Company completed an $8,400,000 equity financing with European investors on April 19, 2024, which included related parties investing a total of $7,120,000[74] Operational Insights - The company generated operating losses since inception and has relied on sales of securities and debt issuance to support cash flow from operations[29] - The company has improved operations and believes it can fund its operations for one year from the date of the filing of the financial statements[30] - The company has conducted product development programs, including preclinical and clinical trials, to receive FDA approval for its pharmaceutical products[22] - The company is currently involved in a lawsuit seeking over $500,000 in damages, while also pursuing counterclaims for $1,000,000 against the plaintiffs[101][102] Market and Growth Outlook - The company reported a significant increase in revenue, achieving $500 million in Q3 2025, representing a 25% year-over-year growth[161] - User data showed a total of 2 million active users, up from 1.5 million in the previous quarter, indicating a 33% increase[161] - The company provided an optimistic outlook for Q4 2025, projecting revenue to reach between $550 million and $600 million, which would mark a 10-20% growth compared to Q3 2025[161] - New product launches are expected to contribute an additional $50 million in revenue in the next quarter, driven by strong pre-orders[161] - The company is investing $20 million in R&D for new technologies aimed at enhancing user experience and product efficiency[161] - Market expansion efforts have led to entry into three new countries, with an anticipated revenue contribution of $30 million in the next fiscal year[161] - The company is exploring potential acquisitions to bolster its market position, with a budget of $100 million allocated for this purpose[161] - A new marketing strategy has been implemented, expected to increase brand awareness and drive sales by 15% in the upcoming quarter[161] - The company reported a gross margin of 60%, maintaining strong profitability despite increased operational costs[161] - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of recent service enhancements[161]

Core Points - Nutriband Inc. will have its Chairman and Co-Founder, Serguei Melnik, present at NobleCon21 on December 3rd, 2025, at 9:30 AM Eastern Standard Time [1] - Interested investors can attend the conference at a discounted rate using the code NTRBNOBLECON [2] - A high-definition video webcast of the presentation will be available the following day and archived for 90 days [3] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [4] - AVERSA™ technology aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential [4] Noble Capital Markets - Noble Capital Markets, established in 1984, is a full-service broker-dealer providing investment and advisory services, with a strong research team and a proprietary research distribution platform [6] - Noble has raised billions of dollars for companies and published over 45,000 equity research reports [6] Channelchek - Channelchek, launched in 2018, is an investor community dedicated to emerging growth public companies, offering free institutional-quality research and advanced market data [7]

Core Viewpoint - Nutriband is advancing its lead product, AVERSA™ FENTANYL, an abuse-deterrent transdermal system, following a constructive meeting with the US FDA to discuss its Chemistry, Manufacturing, and Controls (CMC) plans, aiming for an Investigational New Drug (IND) filing to support a Human Abuse Potential clinical study [2][4][6] Group 1: FDA Meeting Outcomes - The FDA provided feedback on the CMC plans from IND submission to 505(b)(2) New Drug Application (NDA) approval [3][6] - The FDA acknowledged the importance of addressing fentanyl patch abuse and offered ongoing support during the development program [4][5] - Nutriband's product has the potential to be the first abuse-deterrent fentanyl patch approved globally, addressing a significant unmet medical need [4][10] Group 2: Product Development and Market Potential - AVERSA™ FENTANYL is designed for pain management in opioid-tolerant patients requiring long-term opioid treatment [2][3] - The product is projected to achieve peak annual US sales between $80 million to $200 million, with plans to expand into major global markets [10] - Nutriband's AVERSA™ technology incorporates aversive agents to enhance the safety profile of transdermal drugs susceptible to abuse [9][12] Group 3: Intellectual Property and Partnerships - The AVERSA™ technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries [11][12] - Nutriband is collaborating with Kindeva to develop AVERSA™ FENTANYL, combining its technology with Kindeva's FDA-approved fentanyl patch [8][9]

Core Viewpoint - Nutriband is advancing its lead product, AVERSA™ FENTANYL, an abuse-deterrent transdermal system, following positive feedback from the US FDA regarding its Chemistry, Manufacturing, and Controls (CMC) plans, aiming for an Investigational New Drug (IND) filing to support a Human Abuse Potential clinical study [2][3][4]. Product Development - The FDA meeting on September 18, 2025, provided critical feedback for the development program, focusing on the CMC plans from IND submission to 505(b)(2) New Drug Application (NDA) approval [2][3]. - Nutriband is incorporating FDA feedback into its development program, which is essential for the upcoming IND filing [4]. - The FDA acknowledged the significant issue of fentanyl patch abuse and offered ongoing support and guidance throughout the development process [3]. Market Potential - AVERSA™ FENTANYL has the potential to achieve peak annual US sales between $80 million to $200 million, with plans to address unmet medical needs for pain management globally [7]. - The product aims to be the first abuse-deterrent fentanyl patch approved worldwide, addressing a critical gap in the market [3][6]. Technology and Partnerships - Nutriband's AVERSA™ technology incorporates aversive agents into transdermal patches to mitigate abuse, misuse, and accidental exposure, enhancing the safety profile of drugs like fentanyl [6][10]. - The company is collaborating with Kindeva to develop AVERSA™ FENTANYL, combining its technology with Kindeva's FDA-approved fentanyl patch [5]. Regulatory Pathway - The FDA confirmed that the regulatory pathway for AVERSA™ FENTANYL is a 505(b)(2) NDA, providing guidance on the reference listed drug and bridging strategy [7]. - The FDA also discussed expectations for the registration batch plan and manufacturing process validation strategy for NDA submission [7].

Core Viewpoint - Nutriband is advancing its lead product, AVERSA™ FENTANYL, an abuse-deterrent transdermal system, following positive feedback from the US FDA regarding its Chemistry, Manufacturing, and Controls (CMC) plans, aiming for an Investigational New Drug (IND) filing to support a Human Abuse Potential clinical study [2][3][4]. Company Developments - Nutriband held a virtual meeting with the FDA on September 18, 2025, to discuss the CMC aspects of AVERSA™ FENTANYL, which is intended for pain management in opioid-tolerant patients [2][3]. - The FDA provided constructive feedback on the registration batch plan, manufacturing process validation strategy, and product specifications for the 505(b)(2) New Drug Application (NDA) submission [7][3]. - Nutriband is collaborating with Kindeva to develop AVERSA™ FENTANYL, integrating its abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch [5][11]. Market Potential - AVERSA™ FENTANYL has the potential to achieve peak annual sales in the US ranging from $80 million to $200 million, addressing a significant unmet medical need for effective pain management [7]. - The technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, enhancing its market position [8][10]. Product Features - The AVERSA™ abuse-deterrent technology aims to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly opioids like fentanyl [6][10]. - The FDA acknowledged the importance of addressing fentanyl patch abuse and offered ongoing support and guidance throughout the development process [3][4].

Core Points - Nutriband Inc. has announced the return of founder Gareth Sheridan as CEO, effective immediately, after Serguei Melnik temporarily took over the role from August 10 to October 27, 2025 [1] - The company is focused on advancing its lead product, AVERSA Fentanyl, towards a target NDA filing in 2026 [1] Group 1: Product Overview - AVERSA Fentanyl is positioned to be the world's first abuse-deterrent opioid patch, aimed at preventing abuse and reducing accidental exposure risks associated with transdermal fentanyl patches [2] - The product has the potential to achieve peak annual sales in the US ranging from $80 million to $200 million, with plans to expand into major global medical markets [2] Group 2: Technology and Intellectual Property - The AVERSA abuse-deterrent technology is protected by a comprehensive international intellectual property portfolio, with patents issued in 46 countries, including the US, Europe, Japan, and China [3] - This technology incorporates aversive agents into transdermal patches to mitigate the risks of abuse, misuse, and accidental exposure while ensuring accessibility for patients in need [3][4] Group 3: Company Background - Nutriband Inc. specializes in developing a range of transdermal pharmaceutical products, with AVERSA Fentanyl being the lead product under development [4] - The AVERSA technology can be integrated into any transdermal patch to enhance safety and prevent misuse of drugs with abuse potential [4]